Population Modeling Integrating Pharmacokinetics, Pharmacodynamics, Pharmacogenetics, and Clinical Outcome in Patients With Sunitinib‐Treated Cancer

The tyrosine kinase inhibitor sunitinib is used as first‐line therapy in patients with metastasized renal cell carcinoma (mRCC), given in fixed‐dose regimens despite its high variability in pharmacokinetics (PKs). Interindividual variability of drug exposure may be responsible for differences in res...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:CPT Pharmacometrics Syst Pharmacol
Main Authors: Diekstra, MH, Fritsch, A, Kanefendt, F, Swen, JJ, Moes, DJAR, Sörgel, F, Kinzig, M, Stelzer, C, Schindele, D, Gauler, T, Hauser, S, Houtsma, D, Roessler, M, Moritz, B, Mross, K, Bergmann, L, Oosterwijk, E, Kiemeney, LA, Guchelaar, HJ, Jaehde, U
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley and Sons Inc. 2017
Assuntos:
Original Articles
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5613186/
https://ncbi.nlm.nih.gov/pubmed/28571114
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/psp4.12210
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados